392 related articles for article (PubMed ID: 23964266)
1. Are tau aggregates toxic or protective in tauopathies?
Cowan CM; Mudher A
Front Neurol; 2013; 4():114. PubMed ID: 23964266
[TBL] [Abstract][Full Text] [Related]
2. Rescue from tau-induced neuronal dysfunction produces insoluble tau oligomers.
Cowan CM; Quraishe S; Hands S; Sealey M; Mahajan S; Allan DW; Mudher A
Sci Rep; 2015 Nov; 5():17191. PubMed ID: 26608845
[TBL] [Abstract][Full Text] [Related]
3. What is the pathological significance of tau oligomers?
Cowan CM; Quraishe S; Mudher A
Biochem Soc Trans; 2012 Aug; 40(4):693-7. PubMed ID: 22817718
[TBL] [Abstract][Full Text] [Related]
4. Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo.
Cowan CM; Bossing T; Page A; Shepherd D; Mudher A
Acta Neuropathol; 2010 Nov; 120(5):593-604. PubMed ID: 20617325
[TBL] [Abstract][Full Text] [Related]
5. NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.
Quraishe S; Cowan CM; Mudher A
Mol Psychiatry; 2013 Jul; 18(7):834-42. PubMed ID: 23587881
[TBL] [Abstract][Full Text] [Related]
6. Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.
Congdon EE; Lin Y; Rajamohamedsait HB; Shamir DB; Krishnaswamy S; Rajamohamedsait WJ; Rasool S; Gonzalez V; Levenga J; Gu J; Hoeffer C; Sigurdsson EM
Mol Neurodegener; 2016 Aug; 11(1):62. PubMed ID: 27578006
[TBL] [Abstract][Full Text] [Related]
7. High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration.
Wheeler JM; McMillan PJ; Hawk M; Iba M; Robinson L; Xu GJ; Dombroski BA; Jeong D; Dichter MA; Juul H; Loomis E; Raskind M; Leverenz JB; Trojanowski JQ; Lee VM; Schellenberg GD; Kraemer BC
Acta Neuropathol Commun; 2015 Jun; 3():33. PubMed ID: 26041339
[TBL] [Abstract][Full Text] [Related]
8. Tauopathies and tau oligomers.
Takashima A
J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation and oligomerization of α-synuclein associated with GSK-3β activation in the rTg4510 mouse model of tauopathy.
Takaichi Y; Chambers JK; Inoue H; Ano Y; Takashima A; Nakayama H; Uchida K
Acta Neuropathol Commun; 2020 Jun; 8(1):86. PubMed ID: 32560668
[TBL] [Abstract][Full Text] [Related]
10. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
11. A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations
Bardai FH; Wang L; Mutreja Y; Yenjerla M; Gamblin TC; Feany MB
J Neurosci; 2018 Jan; 38(1):108-119. PubMed ID: 29138281
[TBL] [Abstract][Full Text] [Related]
12. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
13. Tau therapeutic strategies for the treatment of Alzheimer's disease.
Churcher I
Curr Top Med Chem; 2006; 6(6):579-95. PubMed ID: 16712493
[TBL] [Abstract][Full Text] [Related]
14. Azure C Targets and Modulates Toxic Tau Oligomers.
Lo Cascio F; Kayed R
ACS Chem Neurosci; 2018 Jun; 9(6):1317-1326. PubMed ID: 29378132
[TBL] [Abstract][Full Text] [Related]
15. Disruption of neuronal function by soluble hyperphosphorylated tau in a Drosophila model of tauopathy.
Cowan CM; Chee F; Shepherd D; Mudher A
Biochem Soc Trans; 2010 Apr; 38(2):564-70. PubMed ID: 20298222
[TBL] [Abstract][Full Text] [Related]
16. Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology.
Rankin CA; Sun Q; Gamblin TC
Mol Neurodegener; 2007 Jun; 2():12. PubMed ID: 17598919
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic grain disease.
Ferrer I; Barrachina M; Tolnay M; Rey MJ; Vidal N; Carmona M; Blanco R; Puig B
Brain Pathol; 2003 Jan; 13(1):62-78. PubMed ID: 12580546
[TBL] [Abstract][Full Text] [Related]
18. Tau Oligomers Neurotoxicity.
Niewiadomska G; Niewiadomski W; Steczkowska M; Gasiorowska A
Life (Basel); 2021 Jan; 11(1):. PubMed ID: 33418848
[TBL] [Abstract][Full Text] [Related]
19. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.
Noble W; Planel E; Zehr C; Olm V; Meyerson J; Suleman F; Gaynor K; Wang L; LaFrancois J; Feinstein B; Burns M; Krishnamurthy P; Wen Y; Bhat R; Lewis J; Dickson D; Duff K
Proc Natl Acad Sci U S A; 2005 May; 102(19):6990-5. PubMed ID: 15867159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
